| Abatacept 10 mg/kg + DMARDs* (n = 218) | Placebo + DMARDs* (n = 99) | |
| Age, years | 53.1 (12.1) | 52.7 (10.9) |
| Female, n (%) | 167 (77) | 79 (80) |
| Caucasian, n (%) | 211 (97) | 92 (93) |
| Duration of RA, years | 12.1 (8.6) | 11.0 (8.7) |
| Tender joints, n | 31.5 (13.3) | 32.3 (13.7) |
| Swollen joints, n | 22.4 (10.4) | 22.2 (10.5) |
| Subject pain assessment (100 mm VAS) | 70.6 (19.4) | 68.2 (19.4) |
| Physical function (HAQ-DI score) | 1.8 (0.6) | 1.8 (0.6) |
| Patient global assessment (100 mm VAS) | 68.6 (19.3) | 68.0 (21.0) |
| Physician global assessment (100 mm VAS) | 67.7 (17.8) | 65.1 (17.6) |
| DAS28 (CRP) | 6.5 (0.8) | 6.4 (0.8) |
| CRP level, mg/dl | 4.6 (3.9) | 3.3 (3.1) |
*Study groups represent treatment received in the double-blind period (6 months). Data are mean (SD) standard deviation unless otherwise specified.
DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; VAS, visual analogue scale; HAQ-DI, Health Assessment Questionnaire Disability Index; DAS28, Disease Activity Score 28; CRP, C-reactive protein.